Description
FULVEKAST
Fulvestrant IP 50 mg
Pre-filled syringes for intramuscular use only
Classification: Anticancer, Antineoplastic
Fulvekast (fulvestrant) is widely accepted and prescribed to treat HER2-positive and HER-2 negative advanced or metastatic breast cancer in postmenopausal women.
It is also used to treat tumors resistant to endocrine therapy or worsened cancers after hormonal therapy.
How does Fulvekast work?
- • Selective Estrogen Receptor Antagonist.
- • It inhibits estrogen hormone, which causes cancer cells to grow.
- • Stops cancer cell growth.
- • Shrink the tumor.
Why choose a Fulvekast prefilled injection?
- • Better convenience – Pre-filled syringes are quick and ready to use.
- • Precise dose- Accurate and safe dosages.
- • Wider Global access – Readily available at varied hospital care settings, public healthcare clinics.
Fulvekast Prefilled Syringe: Advanced Care for Treatment-Resistant Breast Cancer
As a preferred second-line or subsequent-line option, fulvestrant leads to longer progression–free survival in advanced breast cancer in postmenopausal women.
Directly down-regulate the receptor, offering complete blockade.
Has better tolerance and a favorable safety profile.
Contra-indications:
Carefully administer to patients with blood disorders, hypersensitive individuals, hepatic impairment, children, and pregnant or lactating mothers.
Elderly patients who are at risk of osteoporosis.
Vitamin D or Calcium deficiency
Adverse drug effects
- • Risk of bleeding, Sore throat, mouth sores, upset stomach, nausea, loss of appetite, headache, and tiredness.
- • Flushing or redness of the skin at the site of injection
Serious side effects
- • Hepatotoxicity – yellow coloration of urine, jaundice, hepatitis
- • Pulmonary embolism, blood clots
- • Severe necrosis
- • Gastrointestinal perforation, bleeding
- • Fracture or risk of bone demineralization
Important Safety and Monitoring Information
- • To monitor regularly during the therapy
- • Total blood count
- • Hepatic functions
- • Kidney functions
- • Local tissue necrosis
- • Risks of bleeding
- • Thromboembolic events
Warning:
To be used under medical supervision, an oncologist specialist.
Storage
It should be stored at 2-8 degrees Celsius, protected from light.
Aprazer Healthcare: Global Leader in Advanced Oncology Solutions
Aprazer Healthcare, the leader in oncology care, manufactures the widest range of advanced care medicines and the latest innovative solutions.
WHO- GMP certified, assured therapeutic efficacy and quality.
Globally available in 50+ countries
